12,372 trials
Migraine
Primary: Double Blind (DB) Period: Mean Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab — -2.8…
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
Trypanosomiasis, African · Sleeping Sickness · Trypanosoma Brucei Rhodesiense; Infection
Primary: Percentage of Evaluable Patients With Stage 2 r-HAT Who Died by the End of Hospitalization, Considering Only Deaths Possibly Related to r-HAT or Fexinidazole — 0…
Cervical Cancer
Primary: Geometric Mean Concentration (GMC) of Anti-HPV-16 Immunoglobulin G (IgG) Antibodies One Month After the Second Dose — 1507.4; 2408.7; 3326.1; 1352.4 IU/mL
Hematopoietic and Lymphoid Cell Neoplasm
Primary: Cancer and Treatment Distress (CTXD) — 23.4; 22.6 percentage of participants — p=0.90
Frozen Shoulder
Primary: Number of Participants Eligible With Pain Predominant Frozen Shoulder — 39 Participants
Anxiety · Preoperative Anxiety
Primary: Change in the Anxiety Score Using the Visual Analogue Score for Anxiety Between Treatment Arms — 0; 0; 0 score on a scale
Diffuse Large B-Cell Lymphoma
Primary: Overall Survival in Subjects Who Possess the DGM1™ Biomarker — 82; 87 percentage of patients
Dry Eye
Primary: Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS)) — -11.5; -15.0; -17.8; -6.8 score on a scale
COVID
Primary: Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29 — 85.7; 87.5; 74.4 percentage of participants — p=0.2598
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Esophageal Adenocarcinoma
Primary: Number of Participants With Dose-limiting Toxicities (DLT) During the First Cycle of Treatment — 0; 2 Participants
Meningococcal Infections
Primary: Groups 1 and 2: Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y — 131; 189; 565; 120 Titer
Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Participants Meeting Immune Serological Response Criteria to Tetanus Toxoid Antigen — 10; 53.1 percentage of participants
Allergy
Primary: Average Total Combined Score (TCS) During the Birch Pollen Season (BPS) — 5.88; 4.60 score on a scale — p=0.0004
COVID-19 · SARS-CoV-2 Infection · Coronavirus Infection
Primary: Oxygen Free Days Through Day 28. — 9.0; 11.3; 8.1; 10.5 Days